Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Microbicides news


From To
Vaginal implant might stop HIV transmission

Scientists at the University of Waterloo have developed a promising new medical device that could help protect women from HIV. The technology consists of a vaginal implant that basically reduces the amount of targets the virus can latch onto during sex, and may prove a more effective measure than some anti-HIV drugs or condoms in fending off infections.

17 April 2018
New Atlas
CROI 2018: Highlights and what’s next for advocates

Historically, CROI is heavy on basic science and early-phase research. Data from these types of studies were still prominent in 2018, but this year the meeting also broadened its lens from the lab to the ways that different strategies are, or might, have an impact in the context of people's complex lives.

27 March 2018
In the Era of Daily PrEP, Feds May Stop Research Funding Gels, Rings, and Douches for HIV Prevention

It's precisely because of the overwhelming success in recent years of oral PrEP that the future of the anal douche and other sorts of topically applied anti-HIV agents, such as gels and dissolvable films, all loosely termed "microbicides," is suddenly up in the air, if not outright doomed.

07 March 2018
The Body
Genital inflammation reduces efficacy of tenofovir gel against HIV in women

The researchers performed a post hoc prospective analysis of 774 patients who participated in the Centre for the AIDS Program of Research In South Africa (CAPRISA) 004 study, a trial of topical tenofovir gel. McKinnon and colleagues measured concentrations of nine different proinflammatory cytokines from cervicovaginal lavages, and defined genital inflammation using a graduated cytokine store.

28 February 2018
Do HIV-Preventing Microbicides Have a Future in the Age of PrEP?

Courting controversy, the NIH considers a shift away from the development of new vaginal or rectal-based HIV prevention products.

11 December 2017
Vital Microbicides May Soon Be Out of Reach

Whether, when, and how microbicide development proceeds depends on the U.S government, and the federal Division of AIDS has suggested this development may no longer be a priority. It's wrong.

10 November 2017
DAIDS Boss Muses on the Future of HIV Prevention Research

Below are some of Dr. Dieffenbach’s rather intentionally provocative ideas about specific HIV prevention research candidates—challenges and promises, and the questions they may raise for the next clinical trial research network structure.

20 October 2017
Population Council Advances Non-Antiretroviral Multipurpose Prevention Technology For HIV and STI Prevention to Clinical Trial

First in-human clinical trial of griffithsin, a naturally occurring anti-HIV protein, which limits risk of cross-resistance to antiretroviral (ARV) products.

16 October 2017
Population Council
Free Your (and Carl's) Mind: An Open Letter to Anthony Fauci About HIV Prevention Research Priorities

Please Tony, help Carl free his mind to consider microbicides with the same passion and intensity and commitment he has for vaccines and long-acting formulations. He has heard us say these things many times over this year, but he has yet to really listen, I am sorry to say. He seems to listen only when it fits in with his vision.

11 October 2017
The Body Pro
Save Microbicide Research and Development

Ongoing funding and support for vaginal and rectal microbicide research and development is in serious danger! Let NIAID know you want the research to continue.

18 September 2017
← First12345...15Next →
Tell us why you visited aidsmap today

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?


Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.